Toggle light / dark theme

Most of our progress in disease treatment and prevention to date has been the product of the linear process of hit-or-miss efforts to find useful interventions. Because we have lacked tools for systematically exploring all possible treatments, discoveries under this paradigm have owed a lot to chance. Likely the most notable chance breakthrough in medicine was the accidental discovery of penicillin — which opened up the antibiotic revolution and has since saved perhaps as many as 200 million lives. But even when discoveries aren’t literally accidental, it still takes good fortune for researchers to achieve breakthroughs with traditional methods. Without the ability to exhaustively simulate possible drug molecules, researchers have to rely on high-throughput screening and other painstaking laboratory methods, which are much slower and more inefficient.

To be fair, this approach has brought great benefits. A thousand years ago, European life expectancy at birth was just in the twenties, since so many people died in infancy or youth from diseases like cholera and dysentery, which are now easily preventable. By the middle of the nineteenth century, life expectancy in the United Kingdom and the United States had increased to the forties. As of 2023, it has risen to over eighty in much of the developed world. So, we have nearly tripled life expectancy in the past thousand years and doubled it in the past two centuries. This was largely achieved by developing ways to avoid or kill external pathogens — bacteria and viruses that bring disease from outside our bodies.

Today, though, most of this low-hanging fruit has been picked. The remaining sources of disease and disability spring mostly from deep within our own bodies. As cells malfunction and tissues break down, we get conditions like cancer, atherosclerosis, diabetes, and Alzheimer’s. To an extent we can reduce these risks through lifestyle, diet, and supplementation — what I call the first bridge to radical life extension. But those can only delay the inevitable. This is why life expectancy gains in developed countries have slowed since roughly the middle of the twentieth century. For example, from 1,880 to 1900, life expectancy at birth in the United States increased from about thirty-nine to forty-nine, but from 1980 to 2000 — after the focus of medicine had shifted from infectious disease to chronic and degenerative disease — it only increased from seventy-four to seventy-six.

Year 2023 Basically solar will last several billion years and make type 0 civilization resources obsolete by making trillions of dollars in profits with nearly zero emissions.


Between the Covid-19 pandemic, the Ukraine conflict, inflation, and the renewables transition, the 2020s have been a volatile decade for energy. The pandemic reduced demand for electricity and oil all over the world, causing prices to plummet. Then the Ukraine invasion brought sanctions on Russian oil and gas, pushing energy prices up and leaving European countries scrambling (particularly for natural gas). High energy prices have since contributed to inflation, and in many places utility costs are far surpassing inflation. All the while, worry over climate change has continued to mount, with calls to reduce our dependence on fossil fuels growing ever louder.

In short, the energy situation in the US and around the world is a mess. But the International Energy Agency released some good news in its recent World Energy Investment report. The report is compiled annually, and the 2023 version came out at the end of May. For the first time ever, it found that investment in renewables—specifically solar power—will overtake spending on oil.

The IEA estimated that a total of $2.8 trillion will be invested in energy globally this year, with clean energy accounting for more than $1.7 trillion of that total. The “clean” designation includes renewables like wind, solar, and hydro, but also nuclear power, grids, storage, low-emission fuels, efficiency improvements, and electrification (such as replacing combustion-engine cars with electric cars). The remainder of the $2.8 trillion total, about $1 trillion, will go to oil, gas, and coal, with 15 percent going to coal specifically.

The role that Epstein-Barr virus (EBV) plays in the development of multiple sclerosis (MS) may be caused by a higher level of cross-reactivity, where the body’s immune system binds to the wrong target, than previously thought.

In a new study published in PLOS Pathogens, researchers looked at blood samples from people with MS, as well as healthy people infected with EBV and people recovering from glandular fever caused by recent EBV infection.

The study investigated how the immune system deals with EBV infection as part of worldwide efforts to understand how this common virus can lead to the development of multiple sclerosis, following 20 years of mounting evidence showing a link between the two.

Positive life experiences boost brain mitochondrial health, potentially providing protection against certain brain disorders and promoting longevity.

In @MedicalXpress: https://ow.ly/BNn750SrT3c.

In PNAS: https://ow.ly/wT1e50SrT3b.

Mitochondria supply energy to the brain, and the new study shows that…


Psychosocial experiences affect brain health and aging trajectories, but the molecular pathways underlying these associations remain unclear. Normal brain function relies on energy transformation by mitochondria oxidative phosphorylation (OxPhos). Two main lines of evidence position mitochondria both as targets and drivers of psychosocial experiences. On the one hand, chronic stress exposure and mood states may alter multiple aspects of mitochondrial biology; on the other hand, functional variations in mitochondrial OxPhos capacity may alter social behavior, stress reactivity, and mood. But are psychosocial exposures and subjective experiences linked to mitochondrial biology in the human brain?

This single-center longitudinal cohort study has followed known carriers of PRNP pathogenic variants at risk for prion disease, individuals with a close relative who died of genetic prion disease but who have not undergone predictive genetic testing, and controls. All participants were asymptomatic at first visit and returned roughly annually. We determined PRNP genotypes, measured NfL and GFAP in plasma, and RT-QuIC, total PrP, NfL, T-tau, and beta-synuclein in CSF.

Cirrus Therapeutics, the University of Bristol, and London’s Global University Institute of Ophthalmology have discovered a new treatment for age-related macular degeneration (AMD), the leading cause of vision loss among older adults.

Featured on the cover of the journal Science Translational Medicine, this research reveals that boosting a specific protein, IRAK-M, in retinal cells could offer a new and highly effective therapy for AMD.

AMD can severely impact a person’s vision. Patients suffering from AMD often start with blurred vision or seeing a black dot in their central vision, which can ultimately expand to the point where there is no useful central vision. Currently, AMD affects approximately 200 million people worldwide, a number projected to rise to 288 million by 2040 with graying populations. The exact cause of AMD is complex and thought to involve a combination of aging, environmental, and lifestyle factors.

The probe also achieved stable neural recordings in rat brains for up to two years, showing excellent biocompatibility and long-term recording stability, state news agency Xinhua reported.

Cheng Heping, with the Chinese Academy of Sciences and director of the National Centre for Biomedical Imaging Science at Peking University, told Xinhua that the achievement provided a powerful tool for high-throughput simultaneous monitoring of activity in multiple brain regions, and for exploring the relationships between neural activity and behaviour.